Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Jin He, Xiaoyan Sun, Rongjian Nie & Lin Zhao. (2022) Relationship between serum parathyroid hormone levels and abdominal aortic calcification in patients starting hemodialysis who have never taken calcium tablets, calcitriol, or vitamin D analogs. Renal Failure 44:1, pages 1410-1417.
Read now
Read now
Kamyar Kalantar-Zadeh, Christopher S. Hollenbeak, Roy Arguello, Sophie Snyder & Akhtar Ashfaq. (2020) The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3–4 CKD. Journal of Medical Economics 23:3, pages 308-315.
Read now
Read now
Valentina Lorenzoni, Leopoldo Trieste & Giuseppe Turchetti. (2015) The cost–effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet. Expert Review of Pharmacoeconomics & Outcomes Research 15:4, pages 611-624.
Read now
Read now
C.V. Asche, S.E. Marx, J. Kim, S.K. Unni & D. Andress. (2012) Impact of elevated intact parathyroid hormone on mortality and renal disease progression in patients with chronic kidney disease stages 3 and 4. Current Medical Research and Opinion 28:9, pages 1527-1536.
Read now
Read now
Articles from other publishers (22)
Joseph Aoki, Cihan Kaya, Omar Khalid, Tarush Kothari, Mark A. Silberman, Con Skordis, Jonathan Hughes, Jerry Hussong & Mohamed E. Salama. (2023) CKD Progression Prediction in a Diverse US Population: A Machine-Learning Model. Kidney Medicine 5:9, pages 100692.
Crossref
Crossref
Graziella D'Arrigo, Francesca Mallamaci, Patrizia Pizzini, Daniela Leonardis, Giovanni Tripepi & Carmine Zoccali. (2023) CKD-MBD biomarkers and CKD progression: an analysis by the joint model. Nephrology Dialysis Transplantation 38:4, pages 932-938.
Crossref
Crossref
Simona Barbuto, Valentina Perrone, Chiara Veronesi, Melania Dovizio, Fulvia Zappulo, Daniele Vetrano, Sandro Giannini, Maria Fusaro, Domenica Daniela Ancona, Antonietta Barbieri, Fulvio Ferrante, Fabio Lena, Stefano Palcic, Davide Re, Francesca Vittoria Rizzi, Paolo Cogliati, Marco Soro, Luca Degli Esposti & Giuseppe Cianciolo. (2023) Real-World Analysis of Outcomes and Economic Burden in Patients with Chronic Kidney Disease with and without Secondary Hyperparathyroidism among a Sample of the Italian Population. Nutrients 15:2, pages 336.
Crossref
Crossref
Helmut Reichel, Eric Seibert, Frank-Peter Tillmann, Isabella Barck, Astride Grava, Kim Maren Schneider & Dominic Meise. (2022) Economic burden of secondary hyperparathyroidism in Germany: a matched comparison. International Urology and Nephrology 55:5, pages 1291-1300.
Crossref
Crossref
Michael J. Germain, Subir K. Paul, George Fadda, Varshasb Broumand, Andy Nguyen, November H. McGarvey, Matthew D. Gitlin, Charles W. Bishop, Philipp Csomor, Stephen Strugnell & Akhtar Ashfaq. (2022) Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients. BMC Nephrology 23:1.
Crossref
Crossref
Pablo Ureña Torres, María Isabel Troya, Maxime Dauvergne & Jordi Bover. (2022) Independent effects of parathyroid hormone and phosphate levels on hard outcomes in non-dialysis patients: food for thought. Nephrology Dialysis Transplantation 37:4, pages 613-616.
Crossref
Crossref
Milica Bozic, Juan M Diaz-Tocados, Marcelino Bermudez-Lopez, Carles Forné, Cristina Martinez, Elvira Fernandez & José M Valdivielso. (2022) Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrology Dialysis Transplantation 37:4, pages 663-672.
Crossref
Crossref
Markus Ketteler & Patrice Ambühl. (2021) Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease. Journal of Nephrology 34:5, pages 1405-1418.
Crossref
Crossref
Yang Xu, Marie Evans, Marco Soro, Peter Barany & Juan Jesus Carrero. (2021) Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. Clinical Kidney Journal.
Crossref
Crossref
George Fadda, Michael J. Germain, Varshasb Broumand, Andy Nguyen, November McGarvey, Matthew Gitlin, Charles W. Bishop & Akhtar Ashfaq. (2021) Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol. American Journal of Nephrology 52:10-11, pages 798-807.
Crossref
Crossref
Guillaume Jean, Marie Hélène Lafage-Proust, Jean Claude Souberbielle, Sylvain Lechevallier, Patrik Deleaval, Christie Lorriaux, Jean Marc Hurot, Brice Mayor, Manolie Mehdi & Charles Chazot. (2018) Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort. PLOS ONE 13:6, pages e0199140.
Crossref
Crossref
Martin Petkovich & Charles W. Bishop. 2018. Vitamin D. Vitamin D
667
678
.
Guillaume Jean, Éric Daugas, Hubert Roth, Tilman Drueke, Jean-Louis Bouchet, Thierry Hannedouche, Gérard London & Denis Fouque. (2017) La prise en charge des troubles du métabolisme minéral et osseux avant le stade de la dialyse reste encore perfectible. À partir des données de l’Observatoire national du métabolisme minéral et osseux Photo-Graphe. Néphrologie & Thérapeutique 13:6, pages 470-478.
Crossref
Crossref
Sumanee Prakobsuk, Supinda Sirilak, Kotcharat Vipattawat, Pahnwat T. Taweesedt, Vasant Sumethkul, Surasak Kantachuvesiri & Sinee Disthabanchong. (2016) Hyperparathyroidism and increased fractional excretion of phosphate predict allograft loss in long-term kidney transplant recipients. Clinical and Experimental Nephrology 21:5, pages 926-931.
Crossref
Crossref
Giuseppe Turchetti, S. Bellelli, M. Amato, S. Bianchi, P. Conti, A. Cupisti, V. Panichi, A. Rosati & F. Pizzarelli. (2016) The social cost of chronic kidney disease in Italy. The European Journal of Health Economics 18:7, pages 847-858.
Crossref
Crossref
Ahmad Jayedi, Sepideh Soltani & Sakineh Shab-Bidar. (2017) Vitamin D Status and All-Cause Mortality in Patients With Chronic Kidney Disease: A Systematic Review and Dose-Response Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism 102:7, pages 2136-2145.
Crossref
Crossref
Sophie Liabeuf, Nathalie Neirynck, Tilman B. Drüeke, Raymond Vanholder & Ziad A. Massy. (2014) Clinical Studies and Chronic Kidney Disease: What Did we Learn Recently?. Seminars in Nephrology 34:2, pages 164-179.
Crossref
Crossref
Olivier Beauchet, Lise Hélard, Manuel Montero-Odasso, Laure de Decker, Gilles Berrut & Cédric Annweiler. (2013) Hypovitaminosis D in geriatric inpatients: a marker of severity of chronic diseases. Aging Clinical and Experimental Research 24:2, pages 188-192.
Crossref
Crossref
Mario Cozzolino, Markus Ketteler & Daniel Zehnder. (2010) The vitamin D system: a crosstalk between the heart and kidney. European Journal of Heart Failure 12:10, pages 1031-1041.
Crossref
Crossref
Mark Nuijten, Dennis L. Andress, Steven E. Marx, Alistair S. Curry & Raimund Sterz. (2010) Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK. Clinical Drug Investigation 30:8, pages 545-557.
Crossref
Crossref
. (2009) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 16:6, pages 470-480.
Crossref
Crossref
Kamyar Kalantar-Zadeh & Csaba P. Kovesdy. (2009) Clinical Outcomes with Active versus Nutritional Vitamin D Compounds in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology 4:9, pages 1529-1539.
Crossref
Crossref